Equities Analysts Set Expectations for CLDX FY2024 Earnings

Celldex Therapeutics, Inc. (NASDAQ:CLDX) – Analysts at HC Wainwright lifted their FY2024 earnings per share estimates for Celldex Therapeutics in a report released on Thursday, November 7th. HC Wainwright analyst J. Pantginis now anticipates that the biopharmaceutical company will post earnings per share of ($2.39) for the year, up from their prior estimate of ($2.48). HC Wainwright currently has a “Buy” rating and a $80.00 target price on the stock. The consensus estimate for Celldex Therapeutics’ current full-year earnings is ($2.50) per share. HC Wainwright also issued estimates for Celldex Therapeutics’ Q4 2024 earnings at ($0.66) EPS and FY2025 earnings at ($3.02) EPS.

A number of other research analysts have also issued reports on CLDX. Citigroup began coverage on shares of Celldex Therapeutics in a research report on Monday, October 7th. They set a “buy” rating and a $70.00 target price on the stock. Wolfe Research downgraded Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a research report on Friday, September 27th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $67.00 price objective on shares of Celldex Therapeutics in a report on Monday, September 16th. Wells Fargo & Company raised Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, September 26th. Finally, The Goldman Sachs Group assumed coverage on Celldex Therapeutics in a research note on Monday, September 30th. They issued a “neutral” rating and a $45.00 price target for the company. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $62.25.

Celldex Therapeutics Stock Performance

NASDAQ:CLDX opened at $26.21 on Monday. Celldex Therapeutics has a 52 week low of $24.43 and a 52 week high of $53.18. The firm’s 50-day simple moving average is $33.60 and its 200 day simple moving average is $35.79. The firm has a market cap of $1.74 billion, a price-to-earnings ratio of -10.16 and a beta of 1.60.

Hedge Funds Weigh In On Celldex Therapeutics

Institutional investors have recently modified their holdings of the business. Novo Holdings A S boosted its stake in Celldex Therapeutics by 13.4% in the third quarter. Novo Holdings A S now owns 963,663 shares of the biopharmaceutical company’s stock valued at $32,755,000 after buying an additional 113,663 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Celldex Therapeutics by 631.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,087,208 shares of the biopharmaceutical company’s stock valued at $129,571,000 after purchasing an additional 2,664,915 shares during the last quarter. Swiss National Bank increased its position in Celldex Therapeutics by 17.8% during the 1st quarter. Swiss National Bank now owns 114,300 shares of the biopharmaceutical company’s stock worth $4,797,000 after purchasing an additional 17,300 shares in the last quarter. Bellevue Group AG lifted its stake in Celldex Therapeutics by 15.7% in the 1st quarter. Bellevue Group AG now owns 2,796,615 shares of the biopharmaceutical company’s stock valued at $117,374,000 after purchasing an additional 380,319 shares during the last quarter. Finally, AlphaCentric Advisors LLC boosted its position in Celldex Therapeutics by 23.4% in the second quarter. AlphaCentric Advisors LLC now owns 47,500 shares of the biopharmaceutical company’s stock valued at $1,758,000 after buying an additional 9,000 shares in the last quarter.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.